

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/019,353	04/25/2002	John Alfred Wilkinson	B0192/7033	1376
23628 7	90 02/28/2006		EXAMINER	
WOLF GREENFIELD & SACKS, PC			LEVY, NEIL S	
FEDERAL RESERVE PLAZA 600 ATLANTIC AVENUE BOSTON, MA 02210-2211			ART UNIT	PAPER NUMBER
			1615	

DATE MAILED: 02/28/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)		
Office Action Summary		10/019,353	WILKINSON, JOHN ALFRED		
		Examiner	Art Unit		
		NEIL LEVY	1615		
Period fo	The MAILING DATE of this communication app or Reply	pears on the cover sheet with the c	orrespondence address		
A SH WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATES and the may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Depend for reply is specified above, the maximum statutory period ware to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status					
1)[\inf	Responsive to communication(s) filed on 10 Ja	anuary 2006.			
·	This action is FINAL . 2b) This action is non-final.				
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
	closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	53 O.G. 213.		
Disposit	ion of Claims				
5)□ 6)⊠ 7)□	Claim(s) <u>1-4,8,9,11-17,19,33 and 73-93</u> is/are plant of the above claim(s) <u>86</u> is/are withdrawn from Claim(s) <u>1-4,8,9,11-17,19,33 and 73-85,87-93</u> Claim(s) <u>1-4,8,9,11-17,19,33 and 73-93</u> are suited to the claim(s) <u>1-4,8,9,11-17,19,19,33 and 73-93</u> are suited to the claim(s) <u>1-4,8,9,11-17,19,33 and 73-93</u> are suited to the claim(s) <u>1-4,8,9,11-17,19,33 and 73-93</u> are suited to the claim(s) <u>1-4,8,9,11-17,19,19,19,19,19,19,19,19,19,19,19,19,19,</u>	rom consideration.	ı requirement.		
Applicati	ion Papers	•			
10)	The specification is objected to by the Examiner The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the Replacement drawing sheet(s) including the correction The oath or declaration is objected to by the Examiner	epted or b) objected to by the Edrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).		
Priority u	under 35 U.S.C. § 119				
12) [a) [Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority documents application from the International Bureau See the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No ed in this National Stage		
Attachmen	t(e)				
_	e of References Cited (PTO-892)	4) Interview Summary	(PTO-413)		
2) 🔲 Notic 3) 🔲 Inforr	e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	Paper No(s)/Mail Da			

Art Unit: 1615

DETAILED ACTION

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims 86 is withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected speicies, there being no allowable generic or linking claim.

Election was made without traverse in the reply filed on paper # 8.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-4,8,9,11,12,14-17,19,33,73-85,87-93 stand rejected under 35 U.S.C. 103(a) as obvious over Eini et al EP 0495 684 in view of Sine et al 6183766, Rosenberg WO 96/14046, Coats4178372 & Precopio 5858383.

The rejection of record is maintained, in essence, as modified by rejection of 2/25/04.

All of these references are of record. Note that Eini at top of page 13 reports no irritation. Although not stated, it is obvious that either the compositions constitute, besides ectoparrasit controlling efficacy, an antipruritic agent or effect. The instant claim 1 does not specify the agent, either.

Art Unit: 1615

Sine also provides topical compositions, gels, inclusive of the instant LUBRAGEL diluted (col. 1, bottom). Carbomers are also used. (col. 11, top). Sine shows Lubragel to provide superior topical effects, as humectant, at >)1-15%(col 11, lines 35- col12, line 4). Skin care actives include irritation reducts (ccol. 14 b.).

Rosenberg shows one in the art knows claaeansing of skin & hygienic and lice control is obtainable in single formulations (p1), and also utilizes essential oils, sage oil.

C oats is cited to show well known use of aloe vera, as a hypoallergenic component of topical gels, while Precopoio shows incorporation of aloe gel(col. 5, top, exampole 1) withlice control compositions.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made, desiring to utilize lice control compositions, to use one of those well known in the art, as exemplified by the primary references, with selection of the equivalent gel , essential oil, antipruritic & other adjuvants as are common in the topical arts, in order to provide safe, comfortable, non-irritating, combination cleansing/lice control/antimicrobial compositions.

All the critical elements of the instant invention are disclosed. The amounts and proportions of each ingredient are result effective parameters chosen to obtain the desired effects. It would be obvious to vary the form of each ingredient to optimize the effect desired, depending upon the particular pest species and crop interest, reduction of toxicity, cost minimization, enhanced, and prolonged, or synergistic effects.

Applicant has not provided any objective evidence of criticality, non-obvious or unexpected results that the administration of the particular ingredients' or concentrations provides any greater or different level of prior art expectation as claimed, and the use of ingredient for the functionality for which they are known to be used is not a basis for patentabilty.

The instant invention provides well known old art recognized compounds, with well known art recognized effects, applied by well known methods to achieve control over lice, bacteria, & dirt as is well known in the art.

The specific ratios, weights, and additives are result effective parameters subject to control by one with skill in the art, in order to optimize the desired effect, such as enhanced foam, gel stability, thickening, lubricity, moisturizing, pH control, fragrance, and freeze protection.

The instant claims are inclusive of the prior art.

Applicant's arguments filed 1/10/06 have been fully considered but they are not persuasive.. Applicant argues there is no motivation shown in the cited art to arrive at the instant invention. However, none of the ingredients are critical, unobvious or unexpected in control of ectoparasites. The cited art shows combinations of these functions in single formulations to be advantageous & attainable. Some of the components used provide potential irritation, thus the artisan would find it within one's purview to utilize the teaching of the prior art in preparation of human topical ectoparasite control formulations.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NEIL LEVY whose telephone number is 571-272-0619. The examiner can normally be reached on Tuesday-Friday, 7 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, THURMAN PAGE can be reached on 571-272-0602. The fax phone

Application/Control Number: 10/019,353

Art Unit: 1615

number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Primary Examiner Art Unit 1615

Page 5